Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines
M E Lacouture1, V Sibaud2, P A Gerber3, C van den Hurk4, P Fernández-Peñas5, D Santini6, F Jahn7, K Jordan8, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org
Author Affiliations
1Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA.
2Department of Oncodermatology, Claudius Regaud Institute, Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France.
3Department of Dermatology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
4Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
5Department of Dermatology, The University of Sydney, Westmead Hospital, Sydney, Australia.
6Arcispedale Santa Maria Nuova di Reggio Emilia, Reggio Emilia, Italy; Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
7Department of Internal Medicine IV, Hematology, Oncology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
8Department of Medicine V, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
Related papers:
Abstract P5-08-10: Safety and Tolerability of Paxman Scalp Cooling at Lower Temperatures to Improve Efficacy with Anthracycline Chemotherapy
ViewAssociation Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer
ViewScalp Cooling in Preventing Persistent Chemotherapy-Induced Alopecia: A Randomized Controlled Trial
ViewAbstract
Purpose
ESMO published the following guidelines for preventive management of CIA:
Scalp cooling is the only method that has been shown to prevent CIA, at least to a certain extent. Seven out of eight randomised clinical trials resulted in a significant advantage for scalp-cooled patients with 50%-65% of patients developing grade 1 alopecia. In addition, many observational studies and reviews showed the efficacy of scalp cooling using gel caps or devices for a broad range of cytostatics for patients with all stages of various cancers. Scalp cooling has shown greater efficacy with taxane-based regimens, and lower efficacy when anthracyclines are combined with taxanes or with cyclophosphamide.
Related papers
“Dear hair loss” – illness perceptions of female patients with chemotherapy-induced alopecia
Chemotherapy-induced alopecia (CIA) is one of the most common and distressing side effects of chemotherapy treatment. This study aims to assess the illness perceptions of…
(pre-)Clinical research to understand alopecia and improve cooling results
• Authors: international multi-disciplinary special interest group (SIG) on chemotherapy-induced alopecia (CIA) & scalp cooling • Pathobiology of CIA is still not fully understood1 •…
A Clinical and Biological Guide for Understanding Chemotherapy-Induced Alopecia and Its Prevention
Chemotherapy-induced alopecia (CIA) is the most visibly distressing side effect of commonly administered chemotherapeutic agents. Because psychological health has huge relevance to lifestyle, diet, and…
